16th of October 2026

The imperative for operational efficiency in cost-constrained markets

Over the decade, global pharma markets have seen intense pressure on the pricing of manufacturing, driven by government price controls, increased competition from the generics sector and the rising cost of raw materials and regulatory compliance. In India, supplier of approximately 20% of the world’s generic drugs by volume, this stress is particularly acute, compelling manufacturers to streamline their operations to sustain profit margins without compromising product quality.

Modernising pharmaceutical equipment remains one of the most direct and measurable responses to these challenges. While best-in-class facilities achieve an overall equipment effectiveness (OEE) levels of more than 85% through advanced automation, energy-efficient designs, and predictive maintenance strategies[1], older machinery can often operate at as low as 30-50% OEE.

The relationship between modernising machinery reducing manufacturing costs is a complex one. Advanced equipment with higher throughput and shorter changeover times can cut labour costs per unit manufactured, while energy-efficient designs can lower utility expenses[2] equivalent to around 10–20% of total production costs in conventional facilities. The cumulative financial impact of these improvements can be transformative, but what keeps manufacturers from introducing these measures, and how can they do so while maintaining their business as usual?

Pricing pressures and their impact on manufacturing economics

Rising competition from generics creates a pricing environment where manufacturing cost leadership becomes essential for commercial viability, as companies with higher cost structures face margin compression that can render products unprofitable. At the same time, pharma manufacturing inputs such as APIs, excipients and packaging materials have been impacted by disruptions to the supply chain and inflation, alongside stringent regulatory requirements for higher-quality materials.

In the face of an increasingly challenging situation, the pharma industry needs to be competitive about its manufacturing costs to survive. Through India’s National Pharmaceutical Pricing Authority framework, the country is subject to Government price controls and reference pricing systems. These limit what manufacturers can charge for essential and widely prescribed medicines, effectively capping revenue while input costs continue to rise.

Sourcing up to 70% of its APIs from China, India is especially vulnerable to pricing volatility, making it imperative for pharma manufacturers to improve their efficiency in order to offset rising costs of materials. The COVID-19 pandemic and subsequent geopolitical tensions have accelerated efforts towards reshoring and diversifying pharma supply chains, creating further pressures on companies investing in redundant capacity and multi-source qualification, while simultaneously seeking to maintain competitive pricing in end markets.

Regulatory compliance is another significant factor contributing to rising manufacturing costs. Enhanced expectations around best practice have imposed incremental costs on manufacturing operations, as manufacturers look to increase their data integrity, develop more sophisticated process validation methodology and meet evolving environmental and safety regulations. Furthermore, complying with international, multi-agency standards such as those of the FDA and EMA can be especially demanding on resources. The FDA’s quality metrics programme[3] encourages manufacturers to adopt mature quality management practices that improve efficiency and reduce costs, illustrating how regulatory expectations and operational excellence objectives can align.

Optimising processes through advanced machinery and automation

Continuous manufacturing platforms integrate multiple unit operations including feeding, blending, granulation, compression and coating into uninterrupted production flows. This method has shown potential to reduce manufacturing costs by 25–35% compared to traditional batch processing, primarily through reductions in labour, material handling and in-process inventory. Eliminating batch-to-batch interruptions reduces the time equipment spends idling, while integrating analytical technology allows for real-time quality monitoring that reduces off-line testing and accelerates batch release. Adoption of continuous manufacturing has accelerated since 2015[4], and FDA approvals of products manufactured through continuous processes[1] only demonstrate the feasibility of this approach, potentially encouraging broader industry investment.

Automated material handling can further reduce labour costs and improve operational consistency, with guided vehicles and robotic dispensing systems minimising significant labour hours spent moving materials in conventional facilities. Integrating robotics with manufacturing execution systems enables multiple automated units to run in coordination with each other, optimising production scheduling and minimising equipment idle time. The labour savings that automation achieve are particularly beneficial in high-wage manufacturing environments, while reducing variability introduced by manual operations that can contribute to quality deviations and batch rejections.

Energy-efficient equipment and operational cost reduction

Heating, ventilation, and air conditioning systems in pharmaceutical facilities typically consume 40–60% of total energy, with stringent temperature and humidity control requirements for cleanrooms driving particularly high energy usage. The modernisation of HVAC systems with variable-speed drives, heat recovery technologies and advanced control systems can reduce energy consumption by up to 40%, translating to annual savings of tens of thousands for medium-sized facilities and substantially more for large-scale manufacturing operations.

Pharma manufacturers using energy-efficient motors and equipment can significantly reduce their operational costs, with process and materials efficiency improvements delivering compounding benefits across production. These improvements align with corporate sustainability commitments that increasingly influence investment decisions, considering the ambitious targets in carbon reduction that pharmaceutical companies often set. Energy-efficient equipment investments must account for direct energy savings and indirect operational benefits. These include reduced cooling loads that lower HVAC requirements, lower maintenance costs due to reduced thermal stress on equipment components and potential eligibility for government incentives.

After evaluation, many of these investments deliver payback periods of two to four years compared to standard alternatives, with cumulative savings over equipment lifetimes of ten to fifteen years that substantially exceed initial investment premiums. For pharmaceutical manufacturers in India and other emerging markets which have faced substantial rises in electricity costs, energy efficiency has become a primary driver of decisions around equipment.

Predictive maintenance and industry 4.0 integration

Enabled by Industry 4.0 technologies[5], predictive maintenance reduces manufacturing costs by minimising unplanned equipment downtime and optimising maintenance resource allocation. Traditional preventive maintenance approaches often result in unnecessary maintenance interventions on equipment that remains in good condition, while failing to detect emerging failures that occur between scheduled maintenance intervals. Predictive maintenance[6] overcomes these limitations by continuously monitoring equipment condition through vibration analysis, thermal imaging, oil analysis and process parametre trending. This detects incipient failures before they have the chance to cause unplanned downtime, allowing for maintenance to be scheduled without causing too much disruption to production.

Integrating predictive maintenance with broader Pharma 4.0 platforms enables manufacturing to be optimised far beyond maintenance, encompassing production scheduling, quality management and supply chain coordination. Real-time data on equipment conditions can allow manufacturing execution systems to automatically adjust production schedules, while digital twins (virtual representations of manufacturing lines that simulate operations) support scenario analysis and production parameter optimisation to maximise throughput and maintain quality.

Calculating ROI for equipment investments

Rigorous analysis of the return on investment for upgrading pharmaceutical machinery requires a comprehensive evaluation of all cost and benefit elements across the equipment lifecycle. This extends beyond simple payback calculations, incorporating net present value, internal rate of return and sensitivity analysis that addresses uncertainty in critical assumptions. Direct cost savings from improved efficiency, including reduced labour, energy, materials waste and maintenance expenditure, are the most easily quantified benefits, while indirect benefits require more sophisticated analysis to determine improved quality, reduced inventory and enhanced flexibility.

Events like CPHI & PMEC India offer another way to assess benefits, through equipment demonstrations and direct connection with manufacturers. The show, which runs 23-26 November 2026, is split across two venues, with IEML in Greater Noida providing a home for companies specialising in pharmaceutical machinery. This allows manufacturers to evaluate technologies in person, and directly address any questions about pricing pressures to the people behind the machines. The shows content tracks will also explore evolving technologies and methodologies like Pharma 4.0, helping attendees gain a better understanding of the industry’s future.